Flex Pharma (FLKS) Receives Daily News Sentiment Score of 0.04
Headlines about Flex Pharma (NASDAQ:FLKS) have been trending somewhat positive on Monday, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Flex Pharma earned a news impact score of 0.04 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.5877515583576 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
A number of analysts recently weighed in on FLKS shares. Roth Capital started coverage on shares of Flex Pharma in a report on Thursday, September 7th. They set a “buy” rating and a $14.00 target price for the company. Zacks Investment Research upgraded shares of Flex Pharma from a “sell” rating to a “hold” rating in a report on Monday, August 7th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Flex Pharma presently has a consensus rating of “Buy” and a consensus price target of $15.17.
Shares of Flex Pharma (NASDAQ FLKS) remained flat at $3.44 during mid-day trading on Monday. The company had a trading volume of 40,775 shares. Flex Pharma has a one year low of $3.28 and a one year high of $11.99. The firm’s market cap is $59.46 million. The stock has a 50 day moving average price of $3.46 and a 200-day moving average price of $3.46.
Flex Pharma (NASDAQ:FLKS) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.12. Flex Pharma had a negative net margin of 2,410.97% and a negative return on equity of 64.15%. The company had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $0.46 million. On average, analysts expect that Flex Pharma will post ($2.34) EPS for the current fiscal year.
Flex Pharma Company Profile
Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.
Receive News & Ratings for Flex Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.